Reduced dosing regimens for glaucoma treatment
AssigneeHarrow IP, LLC
InventorDennis Elias Saadeh
Life of this patent
Estimating the term…
Abstract
Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.
Claims20
A method of treating glaucoma in a subject in need thereof comprising:
- administering a pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof to the subject in a single dose once per day.
A method of treating glaucoma in a subject in need thereof comprising:
- stopping administration of a pharmaceutical composition comprising latanoprost or a pharmaceutically acceptable salt thereof every evening and a pharmaceutical composition comprising dorzolamide or a pharmaceutically acceptable salt thereof and timolol or a pharmaceutically acceptable salt thereof two times per day;
- and
- administering a pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof to the subject once per day.
A method of reducing patient burden during treatment for glaucoma in a subject in need thereof comprising:
- stopping administration of a pharmaceutical composition comprising latanoprost or a pharmaceutically acceptable salt thereof every other evening and a pharmaceutical composition comprising dorzolamide or a pharmaceutically acceptable salt thereof and timolol or a pharmaceutically acceptable salt thereof every morning;
- and
- administering a pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof to the subject once per day.
Dependencies are inferred from the claim text.